CRISPR Therapeutics
CRSP
CRSP
446 hedge funds and large institutions have $3.21B invested in CRISPR Therapeutics in 2024 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 157 increasing their positions, 127 reducing their positions, and 75 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
7% less funds holding
Funds holding: 481 → 446 (-35)
22% less capital invested
Capital invested by funds: $4.1B → $3.21B (-$881M)
35% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 75
Holders
446
Holding in Top 10
5
Calls
$127M
Puts
$119M
Top Buyers
| 1 | +$48.5M | |
| 2 | +$31.5M | |
| 3 | +$28.6M | |
| 4 |
BlackRock
New York
|
+$12.5M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$10.8M |
Top Sellers
| 1 | -$28.6M | |
| 2 | -$26.4M | |
| 3 | -$20.4M | |
| 4 |
Barclays
London,
United Kingdom
|
-$10.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.7M |